Global Erythropoietin Stimulating Agents Market 2022-2026

Global Erythropoietin Stimulating Agents Market 2022-2026

Technavio has been monitoring the erythropoietin stimulating agents market and it is poised to grow by $ 4.74 bn during 2022-2026, accelerating at a CAGR of 8.9% during the forecast period. Our report on the erythropoietin stimulating agents market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis of the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the presence of a large pool of CKD patients, rising applications in HIV infections and end-stage renal disorder, risks of thrombosis, during surgeries, and pure red cell aplasia.

The erythropoietin stimulating agents market analysis includes type segment and geographic landscape.

Technavio's erythropoietin stimulating agents market is segmented as below:

By Type

• Epoetin alfa
• Epoetin beta
• Darbepoetin alfa
• Others

By Geographical Landscape

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the growing number of CKD dialysis centers in developing economies as one of the prime reasons driving the erythropoietin stimulating agents market growth during the next few years. Also, increasing instances of strategic collaborations among vendors and the rising number of drugs in the pipeline will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the erythropoietin stimulating agents market covers the following areas:

• Erythropoietin stimulating agents market sizing
• Erythropoietin stimulating agents market forecast
• Erythropoietin stimulating agents market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading erythropoietin stimulating agents market vendors that include 3SBio Inc., Akebia Therapeutics Inc., Amgen Inc., Biocon Ltd., Biosidus SA, Dr. Reddys Laboratories Ltd., F. Hoffmann La Roche Ltd., Johnson and Johnson, LG Chem Ltd., Nanogen Pharmaceutical Biotechnology, Novartis AG, Pfizer Inc., Pieris Pharmaceuticals Inc., Reliance Industries Ltd., Thermo Fisher Scientific Inc., and Zydus Lifesciences Ltd. Also, the erythropoietin stimulating agents market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.